Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$0.88
-$0.08(-4.52%)
At close: 4:00 PM EDT
$0.88
-$0.08(-4.52%)
Day’s Range― - ―
52-Week Range$0.84 - $4.31
Previous CloseN/A
Volume624.38K
Average Volume (3M)8.25M
Market Cap
$412.31M
Enterprise Value$181.53M
Total Cash (Recent Filing)$84.03M
Total Debt (Recent Filing)$27.82M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Oct 27, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding127,255,226
10 Day Avg. Volume9,816,780
30 Day Avg. Volume8,253,907
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue955.41
Enterprise Value/Gross Profit-103.91
Enterprise Value/Ebitda-3.38
Forecast
1Y Price Target
$3.83Price Target Upside335.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$536.25K
Bulls Say, Bears Say
Bulls Say
Proteoform Technology DifferentiationDemonstrated proteoform resolution and substantially higher reproducibility could give Nautilus a differentiated position in proteomics research. If validated across additional assays, this capability may support customer adoption, strengthen scientific credibility, and underpin recurring instrument and consumable demand.
Proteoform Commercialization RoadmapThe shift toward proteoforms is supported by a defined product roadmap, increased staffing, and multiple planned assays. A broader assay menu can improve platform utility, support repeat customer usage, and create a more credible foundation for eventual instrument, consumable, and software revenue.
Cost DisciplineLower operating expenses and improved net loss demonstrate management is controlling spending while continuing platform development. Sustained discipline can extend financial flexibility, preserve resources for priority proteoform programs, and reduce the pace at which commercialization efforts consume capital.
Bears Say
Minimal Commercial RevenueRevenue remains extremely small relative to the company’s operating cost base, showing that commercialization has not yet reached meaningful scale. This leaves Nautilus dependent on future product adoption and successful execution before recurring instrument, consumable, and service revenue can support the business.
Cash Burn And Financing RiskNautilus continues to consume substantial cash while management anticipates additional fundraising, and the new equity facility creates a mechanism for future share issuance. Capital access may support development, but financing needs can increase dilution risk and constrain strategic flexibility if commercialization is delayed.
Broadscale Application DelayThe broadscale delay postpones a potentially important application area and extends the period before the platform can address a wider customer market. Continued probe, model, and architecture work increases execution uncertainty and may defer broader instrument placements, assay revenue, and customer expansion.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.84 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $412.31M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Oct 27, 2026 which is tomorrow.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Jul 28, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 127,255,226 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went down -27.711%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (335.61% Upside)
$3.83 (335.61% Upside)
Blogger Sentiment
Neutral
NAUT Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 960.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.2%
Last 30 Days ▲ 108.1%
Last 30 Days ▲ 108.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.44%
12-Months-Change
Fundamentals
Return on Equity
-37.58%
Trailing 12-Months
Asset Growth
-23.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong technical and scientific momentum around proteoform capabilities (unique resolution, reproducible assays, collaborations, and a clear proteoform commercialization roadmap) and demonstrates cost discipline. However, meaningful commercial revenues remain nascent, the broadscale application is delayed and requires long-duration work, the commercial organization is small, and the company expects to need additional capital before mid-2027. The positives on technology, customer enthusiasm, and a staged product launch are balanced by execution and financing risks tied to broadscale delays and limited near-term revenue.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$3.83
▲(335.61% Upside)
Technical Analysis
Ownership Overview
45.20% Insiders
2.79% Mutual Funds
0.62% Other Institutional Investors
47.27% Public Companies and
Individual Investors